Last month the Cochrane Developmental, Psychosocial and Learning Problems Group published the most comprehensive assessment to date on the benefits and harms of a widely prescribed drug used to treat Attention Deficit Hyperactivity Disorder (ADHD). ADHD is one of the most commonly diagnosed childhood disorders and is estimated to affect about five per cent of children. It’s not surprising then that the Methylphenidate for children and adolescents with ADHD review has sparked debate and attracted media attention around the globe. Here in Australia, Sydney-based review author Donna Gillies caught up with Norman Swan to discuss the review findings on ABC RN’s Health Report.